Speaker Profile
CSO & COO, Clear Labs
Biography
As Chief Scientific Officer for Clear Labs, Dr. Khaksar leads the vision and strategy for talented teams of dedicated scientists who make life healthier through the application of genomics and intelligent analytics. From a leadership perspective, he prioritize team culture and empower my team members to maximize their talents and push the bounds of what's possible. As a scientist and researcher, Dr. Khaksar have deep insights into the world of health, biotechnology, and next generation sequencing, and Ihe continue to contribute to the world of academia as an adjunct faculty member at Rutgers University. Dr. Khaksar like to leave a legacybyraising the quality of life and health of the world's population. Throughhis work at Clear Labs, they have made a huge impact on foodsafety. Dr. Khaksar aim to expand that impact by using my skills toimprove clinicaland pharmaceutical genomics and their effectiveness inpublic health.
Sequencing Technologies Showcase:
Clear Labs
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applicationstodeliver increased clarity.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• John Quackenbush, Harvard
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Foundation Models of Human Cancer Biology to Predict Clinical Outcomes
• Ron Alfa, Noetik
Mechanistic Modeling of the Human Immune System: A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, CytoReason
Biological Foundation Models: Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
From Prediction to Translation: AI and In Vivo Validation to Improve Drug Development Success
• Gabriel Musso, BioSymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development and Advancing Precision Medicine
• Chair: Shivanni Kummar, PATHOMIQ
• Dale Muzzey, Myriad Genetics
• Sanoj Punnen, University of Miami
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug? Closing the Loop from Drug Discovery to Development
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI: From Genomic Data to Therapeutic Insights
• Lisa Gurry, GeneDx
Limited Sample Models for Faster Lead Discovery, High Accuracy, and Regulatory Grade AI
• Lalin Theverapperuma, Expert Intelligence
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
